Medical Journal of Dr. D.Y. Patil Vidyapeeth

BRIEF COMMUNICATION
Year
: 2022  |  Volume : 15  |  Issue : 7  |  Page : 95--96

ELISA IgG versus CMIA IgG for detection of SARS-CoV-2-specific antibodies in COVID-19 patients


Pathum Sookaromdee1, Viroj Wiwanitkit2,  
1 TWS Center, Bangkok, Thailand
2 Dr. D.Y. Patil University, Pune, Maharashtra, India; Joseph Ayobalola University, Ikeji, Arakeji, Nigeria

Correspondence Address:
Pathum Sookaromdee
TWS Center, Bangkok
Thailand

Abstract

COVID-19 is an important coronavirus infection. The detection of SARS-CoV-2-specific antibodies is important in laboratory medicine. Several serological tests are available. Some serological tests such as ELISA IgG versus CMIA IgG are used as standard references for rapid diagnostic immunoassay. Here, the authors reappraised on the diagnostic property of ELISA IgG versus CMIA IgG for the detection of SARS-CoV-2-specific antibodies in COVID-19 patients. According to the analysis, CMIA IgG has a higher sensitivity and ELISA IgG has a higher specificity. Therefore, CMIA IgG is more appropriate for screening purpose.



How to cite this article:
Sookaromdee P, Wiwanitkit V. ELISA IgG versus CMIA IgG for detection of SARS-CoV-2-specific antibodies in COVID-19 patients.Med J DY Patil Vidyapeeth 2022;15:95-96


How to cite this URL:
Sookaromdee P, Wiwanitkit V. ELISA IgG versus CMIA IgG for detection of SARS-CoV-2-specific antibodies in COVID-19 patients. Med J DY Patil Vidyapeeth [serial online] 2022 [cited 2022 Dec 5 ];15:95-96
Available from: https://www.mjdrdypv.org/text.asp?2022/15/7/95/336817


Full Text



 Introduction



COVID-19 is an important coronavirus infection that has been occurred since 2019. At present, more than 120 million COVID-19 cases are accumulated reported worldwide. For the management of COVID-19, the diagnosis of disease is very important. The detection of SARS-CoV-2-specific antibodies is important in laboratory medicine.[1] Several serological tests are available.[2],[3] Some serological tests such as ELISA IgG versus CMIA IgG are used as standard references for rapid diagnostic immunoassay.[4] Here, the authors reappraised on the diagnostic property of ELISA IgG versus CMIA IgG for the detection of SARS-CoV-2-specific antibodies in COVID-19 patients. According to the analysis, CMIA IgG has a higher sensitivity and ELISA IgG has a higher specificity. Therefore, CMIA IgG is more appropriate for screening purpose.

 Materials and Methods



The authors studied on the diagnostic test of ELISA IgG (EUROIMMUN, Lubeck, Germany) versus CMIA IgG (Abbott Ireland Diagnostics Division, Sligo, Ireland) for detection of SARS-CoV-2-specific antibodies in COVID-19 patients. The appraisal is done on cross-sectional data from 245 patients with SARS-CoV-2 infection confirmation by real-time reverse transcriptase-polymerase chain reaction. A direct comparison of diagnostic sensitivity and specificity is done. This work is a reappraisal analysis on available laboratory data, and there is no collection of personal information of the patients. The study protocol was approved by the local Research Ethics.

 Results



Comparing between ELISA IgG and CMIA IgG [Table 1], ELISA IgG has a higher sensitivity (0.9%) but lower specificity (10.6%) than CMIA IgG.{Table 1}

 Discussion



Serological diagnosis of COVID-19 is widely used at present. Many new diagnostic tools are available. The rapid serodiagnosis point of care testing becomes a useful tool. In our setting, the rapid test is usually referred to the standard diagnosis by ELISA IgG or CMIA.[4] Of interest, although both ELISA IgG and CMIA IgG tests are mentioned as gold standard,[2],[3],[4] there are differences in diagnostic properties of both tests. Here, the authors perform a reappraisal analysis for comparing between ELISA IgG and CMIA IgG for the detection of SARS-CoV-2-specific antibodies in COVID-19 patients.

According to the analysis, CMIA IgG has a higher sensitivity and ELISA IgG has a higher specificity. Therefore, CMIA IgG is more appropriate for screening purpose. This observation is concordant with a recent report that ELISA IgG test is superior to other immunological tests for screening for COVID-19.[5]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Ciotti M, Benedetti F, Zella D, Angeletti S, Ciccozzi M, Bernardini S. SARS-CoV-2 infection and the COVID-19 pandemic emergency: The importance of diagnostic methods. Chemotherapy 2021;66:17-23.
2Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections-The state of the art. Emerg Microbes Infect 2020;9:747-56.
3Zainol Rashid Z, Othman SN, Abdul Samat MN, Ali UK, Wong KK. Diagnostic performance of COVID-19 serology assays. Malays J Pathol 2020;42:13-21.
4Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Sudhinaraset N, Chirathaworn C, et al. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients. Virol J 2021;18:52.
5Jahrsdörfer B, Kroschel J, Ludwig C, Corman VM, Schwarz T, Körper S, et al. Independent side-by-side validation and comparison of 4 serological platforms for SARS-CoV-2 Antibody Testing. J Infect Dis 2021;223:796-801.